Regeneron Pharmaceuticals, Inc (USA)

Regeneron Pharmaceuticals, Inc is a biotechnology company that invents, develops and commercializes medicines for people with serious diseases. Founded in 1988 and led by physician-scientists, the company has spent more than 35 years building its research capabilities largely in-house: almost all of its approved treatments and product candidates in development were generated in its own laboratories.

The company employs more than 15,000 people, among them over 1,400 holding MDs and/or PhDs. Its scientific work spans antibody discovery, fully human antibody engineering, bispecific antibody development, genetics and genomics, genetic medicine platforms and data-powered scientific insight. Proprietary tools include VelociSuite®, a set of technologies for producing optimised fully human antibodies and new classes of bispecific antibodies; the Regeneron Genetics Center® (RGC), which applies genetics research to guide drug development; and genetic medicine platforms for exploring new therapeutic modalities.

Regeneron's therapeutic areas cover ophthalmology, allergy and inflammation, oncology, cardiovascular and metabolic diseases, neurology, hematology, infectious diseases and rare diseases. The company operates a global network and describes its culture as centred on a relentless focus on science and on translating research into medicines.